keyword
MENU ▼
Read by QxMD icon Read
search

Chronic myeloid leukaemia

keyword
https://www.readbyqxmd.com/read/27911727/role-of-the-bone-morphogenic-protein-pathway-in-developmental-haemopoiesis-and-leukaemogenesis
#1
REVIEW
Parto Toofan, Helen Wheadon
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage. Chronic myeloid leukaemia (CML) arises from a genetic alteration in a normal haemopoietic stem cell (HSC) giving rise to a leukaemic stem cell (LSC) within the bone marrow (BM) 'niche'. CML is characterised by the presence of the oncogenic tyrosine kinase fusion protein breakpoint cluster region-abelson murine leukaemia viral oncogene homolog 1 (BCR-ABL), which is responsible for driving the disease through activation of downstream signal transduction pathways...
October 15, 2016: Biochemical Society Transactions
https://www.readbyqxmd.com/read/27909345/cardiologist-s-perspective-to-the-european-leukemianet-recommendations-for-the-management-and-avoidance-of-adverse-events-of-treatment-in-chronic-myeloid-leukaemia
#2
C Constance, L Trudeau, E M Jolicoeur, D Langleben, A Rivard, R Chehayeb, M-A Côté, D Delgado
No abstract text is available yet for this article.
December 2, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27899952/prognostic-and-predictive-implications-of-sokal-euro-and-eutos-scores-in-chronic-myeloid-leukaemia-in-the-imatinib-era-experience-from-a-tertiary-oncology-centre-in-southern-india
#3
Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Govind Babu Kanakasetty, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Rajeev Krishnappa Lakkavalli, Lokesh N Kadabur, Rudresha Antapura Haleshappa
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder. Over the years many prognostic models have been developed to better risk stratify this disease at baseline. Sokal, Euro, and EUTOS scores were developed in varied populations initially receiving various therapies. Here we try to identify their predictive and prognostic implication in a larger population of Indian patients with CML-CP (chronic phase) in the imatinib era.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27895079/anterior-chamber-exudation-in-chronic-myeloid-leukaemia
#4
Ravi Bypareddy, Brijesh Takkar, Shorya Vardhan Azad, Rohan Chawla
Anterior chamber leukaemic hypopyon is a rare occurrence in chronic myeloid leukaemia. We discuss two cases marked by rapid exudation inside the anterior chamber, which were subsequently diagnosed as chronic myeloid leukaemia. The hypopyon in both the cases resolved on induction of chemotherapy.
November 28, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27890073/switching-to-nilotinib-versus-imatinib-dose-escalation-in-patients-with-chronic-myeloid-leukaemia-in-chronic-phase-with-suboptimal-response-to-imatinib-lasor-a-randomised-open-label-trial
#5
Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, Jose Luis Lopez, Eduardo Bullorsky, Sandip Shah, Xiaojun Huang, K Govind Babu, Kudrat Abdulkadyrov, José Salvador Rodrigues de Oliveira, Zhi-Xiang Shen, Tomasz Sacha, Israel Bendit, Zhizhou Liang, Tina Owugah, Tomasz Szczudlo, Sadhvi Khanna, Rafik Fellague-Chebra, Philipp D le Coutre
BACKGROUND: Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response remains undetermined. This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib dose escalation for patients with suboptimal cytogenetic response on imatinib. METHODS: We did a phase 3, open-label, randomised trial in patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response to imatinib according to the 2009 European LeukemiaNet criteria, in Latin America, Europe, and Asia (59 hospitals and care centres in 12 countries)...
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27890072/nilotinib-against-high-dose-imatinib-for-salvage-therapy-of-chronic-myeloid-leukaemia
#6
Simona Soverini, Michele Baccarani, Giovanni Martinelli
No abstract text is available yet for this article.
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27879990/sequential-chemotherapy-followed-by-reduced-intensity-conditioning-and-allogeneic-haematopoietic-stem-cell-transplantation-in-adult-patients-with-relapse-or-refractory-acute-myeloid-leukaemia-a-survey-from-the-acute-leukaemia-working-party-of-ebmt
#7
Olle Ringdén, Myriam Labopin, Christoph Schmid, Behnam Sadeghi, Emmanuelle Polge, Johanna Tischer, Arnold Ganser, Mauricette Michallet, Lothar Kanz, Rainer Schwerdtfeger, Arnon Nagler, Mohamad Mohty
This study analysed the outcome of 267 patients with relapse/refractory acute myeloid leukaemia (AML) who received sequential chemotherapy including fludarabine, cytarabine and amsacrine followed by reduced-intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). The transplants in 77 patients were from matched sibling donors (MSDs) and those in 190 patients were from matched unrelated donors. Most patients (94·3%) were given anti-T-cell antibodies. The incidence of acute graft-versus-host disease (GVHD) of grades II-IV was 32·1% and that of chronic GVHD was 30·2%...
November 23, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27843612/tki-induced-pure-red-cell-aplasia-first-case-report-of-pure-red-cell-aplasia-with-both-imatinib-and-nilotinib
#8
Bishesh Sharma Poudyal, Sampurna Tuladhar, Bishal Gyawali
Tyrosine-kinase inhibitors (TKIs) represent the only hopes for long-term survival for patients with chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours. Thus, uninterrupted use of TKIs is of importance in such patients. Pure red cell aplasia (PRCA) is a rare disorder, not previously known to be associated with TKIs. We present, to the best of our knowledge, the first case of a patient with CML who developed PRCA secondary to both imatinib and nilotinib. Although PRCA was controlled on withdrawal of TKI, TKI continuation in the patient with CML is important...
2016: ESMO Open
https://www.readbyqxmd.com/read/27815431/leukaemia-mortality-and-low-dose-ionising-radiation-in-the-wismut-uranium-miner-cohort-1946-2013
#9
Michaela Kreuzer, Christina Sobotzki, Nora Fenske, James W Marsh, Maria Schnelzer
OBJECTIVES: To examine the risk of death from leukaemia in relation to occupational chronic low-level external and internal radiation exposure in a cohort of 58 972 former German uranium miners with mortality follow-up from 1946 to 2013. METHODS: The red bone marrow (RBM) dose from low-linear energy transfer (LET) (mainly external γ-radiation) and high-LET (mainly radon gas) radiation was estimated based on a job-exposure matrix and biokinetic/dosimetric models...
November 4, 2016: Occupational and Environmental Medicine
https://www.readbyqxmd.com/read/27812246/cml-as-part-of-dual-malignancies-a-retrospective-analysis-possible-mechanisms-and-review-of-literature
#10
Kamal Kant Sahu, Yanamandra Uday, Amanjit Bal, Neelam Varma, Shano Naseem, Alka Khadwal, Gaurav Prakash, S Varma, Pankaj Malhotra
Introduction of imatinib has changed the outlook of chronic myeloid leukaemia (CML) patients with overall survival approaching general population. Long term survival in CML patients has provided an opportunity to better study natural history and long term complications of disease as well as the treatment modalities. To study the occurrence and association of other malignancies with their outcomes in patients with CML. This is a single centre retrospective study. All CML patients case records registered with haematology clinic of a tertiary care centre in North India from 2001 to 2014 were perused and evaluated for dual malignancies...
December 2016: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/27806681/relationship-between-cigarette-smoking-and-risk-of-chronic-myeloid-leukaemia-a-meta-analysis-of-epidemiological-studies
#11
Ling Qin, Hui-Yang Deng, Sheng-Jiang Chen, Wei Wei
OBJECTIVE: Previous epidemiologic studies that have been reported on the association between cigarette smoking and risk of chronic myeloid leukaemia (CML) have remained controversial. A comprehensive meta-analysis was performed to evaluate smoking as a potential relationship factor and incidence of CML. METHODS: Systematic literatures collected from articles published before August 2015 were searched from PubMed, EMBASE and the Cochrane Library. A total of 10 studies (nine case-controls and one cohort) met inclusion criteria of this meta-analysis...
November 2, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27752053/tyrosine-kinase-inhibitors-in-chronic-myeloid-leukaemia-which-when-for-whom
#12
REVIEW
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Michele Baccarani
The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for the treatment of disease resistance or intolerance to the first-choice or second-choice drug. The availability of different drugs is a major achievement, but means that choices must be made - which can be difficult and questionable at times. The most important end point considered in decision-making regarding treatment for any cancer is overall survival, but additional factors (such as age, prognostic category, safety, or the possibility of achieving treatment-free remission) should be considered when selecting an agent for frontline treatment...
October 18, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27748288/dual-transcripts-of-bcr-abl-different-polymorphisms-in-chronic-myeloid-leukaemia-patients
#13
S Rajashree Nandagopalan, Nivedita Kuila, Sutapa Biswas, Naresh Chandra Pattnayak, Gyanashyam Biswas, Soumen Chakraborty
BACKGROUND & OBJECTIVES: Chronic myeloid leukaemia is (CML) characterized by the presence of a hallmark chromosomal translocation, the Philadelphia chromosome. Although there are many reports available regarding the different variants of BCR-ABL in CML, we studied the co-expression of e13a2 and e14a2 transcripts and a few polymorphisms in CML patients. METHODS: Molecular genetics approach was adapted to screen for polymorphisms, mutation and translocation in BCR, ABL kinase domain and BCR-ABL breakpoint region in 73 CML patients...
May 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27728330/spontaneous-tumor-lysis-syndrome-in-chronic-myeloid-leukaemia-a-case-report
#14
Lincy Vinayan M, Usha Padmini, Balamurughan, Selvamani, K Sivakumar
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27728093/spontaneous-tumor-lysis-syndrome-in-chronic-myeloid-leukaemia-a-case-report
#15
Lincy Vinayan M, Usha Padmini, Balamurughan, Selvamani, K Sivakumar
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27686083/identification-prevention-and-management-of-cardiovascular-risk-in-chronic-myeloid-leukaemia-patients-candidate-to-ponatinib-an-expert-opinion
#16
Massimo Breccia, Patrizia Pregno, Paolo Spallarossa, Eleonora Arboscello, Fabio Ciceri, Mauro Giorgi, Alberto Grossi, Mario Mallardo, Savina Nodari, Stefano Ottolini, Carla Sala, Giovanni Tortorella, Gianantonio Rosti, Fabrizio Pane, Giorgio Minotti, Michele Baccarani
Ponatinib (Iclusig, ARIAD Pharmaceuticals-Incyte Co.) is a third-generation structure-guided tyrosine kinase inhibitor that is approved for treatment of Philadelphia chromosome-positive leukaemias resistant or intolerant to other inhibitors. The clinical use of ponatinib is complicated by the possible development of cardiovascular events, primarily hypertension and arterial or venous thrombotic events. The US Food and Drug Administration and the European Medicine Agency recommend that the cardiovascular profile of patients candidate for ponatinib should be carefully evaluated...
September 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27682603/non-invasive-imaging-of-retinal-blood-flow-in-myeloproliferative-neoplasms
#17
Anne Willerslev, Mathias M Hansen, Oliver Niels Klefter, Ole Weis Bjerrum, Hans C Hasselbalch, Stine N Clemmensen, Michael Larsen, Inger Christine Munch
PURPOSE: To study the circulation in the retinal vessels in patients with blood dyscrasia due to myeloproliferative neoplasms using non-invasive retinal imaging. METHODS: Prospective consecutive case series of seven treatment-naïve patients with chronic myeloid leukaemia (n = 2), polycythemia vera (n = 4), essential thrombocytosis (n = 1) examined before and after cytoreductive treatment. We investigated retinal circulation with motion-contrast imaging, retinal oximetry and spectral-domain optical coherence tomography...
September 29, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27677054/survival-trends-in-childhood-chronic-myeloid-leukaemia-in-southern-eastern-europe-and-the-united-states-of-america
#18
Maria A Karalexi, Margarita Baka, Anton Ryzhov, Anna Zborovskaya, Nadya Dimitrova, Snezana Zivkovic, Sultan Eser, Luis Antunes, Mario Sekerija, Tina Zagar, Joana Bastos, Anna Demetriou, Domenic Agius, Margareta Florea, Daniela Coza, Sophia Polychronopoulou, Eftichia Stiakaki, Maria Moschovi, Emmanuel Hatzipantelis, Maria Kourti, Stelios Graphakos, Maria S Pombo-de-Oliveira, Hans Olov Adami, Eleni Th Petridou
AIM: To assess trends in survival and geographic disparities among children (0-14 years) with chronic myeloid leukaemia (CML) before and after the introduction of molecular therapy, namely tyrosine kinase inhibitors (TKIs) in Southern-Eastern European (SEE) countries and the USA. METHODS: We calculated survival among children with CML, acute lymphoblastic (ALL) and acute myeloid leukaemia (AML) in 14 SEE (1990-2014) cancer registries and the U.S. Surveillance, Epidemiology and End Results Program (SEER, 1990-2012)...
November 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27630882/a-study-of-haemostatic-parameters-in-patients-of-chronic-myeloid-leukaemia
#19
Ankur Jain, Naresh Gupta, Tejinder Singh, Sunita Agarwal
INTRODUCTION: Chronic Myeloid Leukaemia (CML) is characterized by derangement of various components of the haemostatic system resulting in thrombo-haemorrhagic complications. Although less common than other myeloproliferative neoplasms, derangement of various components of the haemostatic system is observed in CML. Haemostatic abnormalities have been described in relation to hyperleucostasis and drugs used to treat CML. However, the correlation between haemostatic derangements and phase of CML is unclear in the literature...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27552679/cepheid-xpert-monitor-platform-for-the-confirmation-of-bcr-abl1-is-conversion-factors-for-the-molecular-monitoring-of-chronic-myeloid-leukaemia
#20
Gareth Gerrard, Hui En Foong, Katherine Mudge, Mary Alikian, Jane F Apperley, Letizia Foroni
Molecular monitoring of BCR-ABL1 expression in chronic myeloid leukaemia (CML) is well established. As the International Scale (IS) normalised BCR-ABL1/ABL1 ratio at 3 months post-treatment is now an important milestone in patients' treatment schedule, the reliable and reproducible measurement of BCR-ABL1 levels is therefore paramount. IS conversion factors (CF) are established via sample exchange and yearly ratification with an external reference laboratory. Since any change to an established IS CF could lead to discontinuity in longitudinal results, we wished to add an internal verification step as an additional safeguard...
October 2016: Leukemia Research
keyword
keyword
19652
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"